Program Description
The management of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) has become increasingly complex due to the rapid evolution of novel immunotherapies. However, the pace of change has led to challenges in staying informed of evidence-based treatment recommendations, sequencing of therapies, and managing adverse effects. Oncology pharmacists are crucial in guiding clinicians on therapy selection and tailoring treatment plans to individual patient needs, but many have limited experience with these novel immunotherapies, making it difficult for them to incorporate patient- and disease-specific factors into treatment decisions. The session will dissect treatment algorithms for both frontline and relapsed/refractory DLBCL, emphasizing considerations for therapy selection, including patient-specific factors, prior treatments, and adverse effect profiles.
Target Audience: Oncology Pharmacist
Type of Activity: Application
Release date: September 30, 2025
Expiration date: September 30, 2026
Learner level: Foundational, Intermediate
Time to complete activity: 1.25 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Explore the role of novel immunotherapies in the management of relapsed/refractory diffuse large B-cell lymphoma (DLBCL), including their mechanisms of action, clinical efficacy, and safety considerations
- Evaluate patient- and disease-specific factors that influence treatment decisions, including eligibility for novel immunotherapies and considerations for tailoring therapy to individual needs
- Examine pharmacist-led approaches for preventing, monitoring, and managing adverse effects related to novel immunotherapies.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here